The ACER1 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population originating from the SK-HEP-1 human hepatoma cell line, designed to disrupt the ACER1 gene encoding alkaline ceramidase 1. This polyclonal loss-of-function model offers a heterogeneous system for investigating ACER1’s role in sphingolipid metabolism and ceramide-driven apoptosis in liver cancer. The polyclonal nature circumvents clonal selection, preserving natural biological variance while ensuring effective target gene disruption across the cell pool.
The SK-HEP-1 host line, established from ascites of a liver adenocarcinoma patient, displays hepatoma characteristics and is widely used in hepatocellular carcinoma research. Its hepatic origin and tumorigenic phenotype make it relevant for studying dysregulated metabolic pathways, especially sphingolipid signaling, in liver cancer. SK-HEP-1 offers a clinically pertinent context for mechanistic studies of hepatocarcinogenesis and for testing ceramide-targeted therapeutics.
ACER1 functions as an alkaline ceramidase that hydrolyzes long-chain ceramides like C24:0- and C24:1-ceramide into sphingosine and fatty acids, controlling the balance between pro-apoptotic ceramides and pro-survival S1P. Its activity is regulated by p53, TNF??, DNA damage, and oxidative stress, and it impacts downstream effectors sphingosine, S1P, p38 MAPK, and caspases. ACER1 interacts with sphingosine kinases SPHK1/2 and BCL2 family proteins within a network that includes ceramide synthases, sphingomyelinases, and S1P receptors (S1PRs) to govern cell fate.
In SK-HEP-1 hepatoma cells, ACER1 knockout halts ceramide hydrolysis, causing accumulation of pro-apoptotic long-chain ceramides and diminished sphingosine/S1P production. This sensitizes cells to apoptosis through heightened caspase activity and p38 MAPK signaling, potentially suppressing tumor growth by tilting the ceramide/S1P axis toward death. With sphingolipid dysregulation common in hepatocellular carcinoma, this model aids in dissecting ceramide rheostat effects on tumor survival and identifying ACER1-linked vulnerabilities.
These polyclonal knockout cells enable a range of assays: Western blot and RT?qPCR for ACER1 confirmation, LC?MS ceramide/sphingoid base profiling, Annexin V flow cytometry and caspase?3/7 activity for apoptosis detection, colony formation for clonogenicity, and xenograft models for in vivo therapeutic studies. They are ideal for investigations into ceramide-induced apoptosis, drug target validation of ceramidase inhibition, and sphingolipid metabolism in liver cancer. For more information, contact Ascent Research.
